.Attribute Medicine, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- medication conjugate (ADC) tisotumab vedotin resulted in improved progression-free as well as general survival, causing FDA approval as well as a new procedure possibility for clients.